20 results about "Disodium Edetate" patented technology

This invention discloses a carbetocin injection solution and its preparation process. The raw materials for the carbetocin injection solution include at least carbetocin, methionine, disodium edetate, an antibacterial agent, a pH adjuster, and a solvent. The pH of the carbetocin injection solution is 4.0-4.5. The concentration of carbetocin is 50 μg / ml-80 μg / ml, the concentration of methionine is 10 mg / ml-20 mg / ml, the concentration of disodium edetate is 5 mg / ml-10 mg / ml, and the concentration of the antibacterial agent is 2 mg / ml-3 mg / ml. By controlling the concentrations of carbetocin, methionine, disodium edetate, and the antibacterial agent, and simultaneously adjusting the pH of the injection solution to 4.0-4.5, this invention eliminates the need for nitrogen purging during the preparation process, thereby enabling the prepared carbetocin injection solution to exhibit high antioxidant properties and stability, allowing for long-term storage at room temperature.

This invention provides an birepiperazole oral solution, wherein the solution comprises birepiperazole 0.4-0.6 mg / ml, disodium edetate 0.1-0.5 mg / ml, methylparaben 1.5-2.0 mg / ml, propylparaben 0.15-0.25 mg / ml, an acidic pH adjuster 2.5-3.5 mg / ml, a flavoring agent 0.8-1.2 mg / ml, propylene glycol 40-60 mg / ml, glycerin 120-180 mg / ml, and a sodium hydroxide solution to adjust the pH to 2.9-3.3. The drug exhibits high stability during preparation, storage, and clinical formulation.

The invention discloses a composition and a preparation method of an epinephrine hydrochloride injection, the formula comprises epinephrine, hydrochloric acid, sodium chloride (for injection), edetate disodium, L (+) tartaric acid, alpha-ketoglutaric acid, sodium hydroxide and water for injection, and the use amount of alpha-ketoglutaric acid is 0.35-0.75 mg / ml. The epinephrine hydrochloride injection disclosed by the invention is simple in composition and stable in quality, the preparation process is simple, convenient and efficient, special equipment and inert gas filling are not needed, and a filled sample is subjected to high-pressure steam sterilization under the condition of 121 DEG C / 12min.

The present application relates to the technical field of gynecological bacteriostatic gel, and particularly relates to a ulipristal bacteriostatic gel and a preparation method thereof; the ulipristal bacteriostatic gel comprises the following components in parts by weight: chlorhexidine acetate 1-3 parts, meihua grass extract 4-8 parts, carbomer 0.8-1.2 parts, triethanolamine 0.4-0.6 parts, penetration enhancer 0.5-1.5 parts, modified nano-silver 0.04-0.07 parts, glycerol 5-8 parts, hydrogenated polyisobutylene 0.03-0.07 parts, disodium edetate 0.1-0.3 parts and purified water in a remainder amount; the chlorhexidine acetate and the meihua grass ethanol extract are compounded at a ratio of 1:(2.5-4), the flavones and polyphenols in the meihua grass can destroy the cell membrane permeability of microorganisms, promote the chlorhexidine acetate to enter the inside of the microorganism, and significantly reduce the minimum bacteriostatic concentration.

A catgut implant for treating ascites and a preparation method thereof belong to the technical field of catgut preparation. Raw materials are as follows in percentage by mass: 27-31% of Gansui Banxia extract, 25-28% of humectant, 27-31% of water, 0.5-0.8% of glycyrrhizic acid, 5-9% of polyacrylic acid sodium, 1.5-4% of carboxymethyl cellulose sodium, 0.9-2.5% of polyvinylpyrrolidone, 0.03-0.06% of disodium edetate, 0.2-1.3% of organic acid, 0.5-0.9% of filling agent and 0.2-2% of transdermal penetration enhancer. The catgut implant improves the production process of catgut, reduces the production cost of catgut, has good formability and adhesion, and prepares Gansui Banxia decoction for treating ascites into catgut implant with controllable quality.

The invention discloses pranoprofen eye drops and a production process thereof. Comprising the following raw material components in parts by weight: 0.1 to 0.5 part of pranoprofen, 1 to 5 parts of vitamin E polyethylene glycol 1000 succinate, 2 to 6 parts of soybean phospholipid, 3 to 8 parts of polyoxyethylated castor oil EL-40, 0.1 to 0.3 part of histidine, 0.2 to 0.6 part of sodium dihydrogen phosphate, 0.3 to 0.7 part of disodium hydrogen phosphate, 2 to 5 parts of glycerol, 1 to 4 parts of polyethylene glycol 400, 0.05 to 0.2 part of sodium hyaluronate, 0.1 to 0.4 part of D-panthenol and 0.01 to 0.03 part of benzalkonium chloride. The injection comprises the following components in parts by weight: 0.05-0.15 part of potassium sorbate, 0.005-0.02 part of epsilon-polylysine, 0.01-0.05 part of edetate disodium, 0.02-0.08 part of vitamin E acetate, 0.005-0.015 part of L-cysteine and the balance of water for injection, and the total weight part of the water for injection is 100 parts. According to the invention, pranoprofen is taken as a core, and vitamin E polyethylene glycol 1000 succinate, soybean phospholipid and polyoxyethylated castor oil EL-40 are adopted for synergistic solubilization, so that the problem of poor water solubility of the medicine is solved; histidine and phosphate are compounded for buffering and are matched with multiple stabilizers, so that the stability of the preparation is improved.

The invention discloses a preparation method of clindamycin phosphate injection, and belongs to the field of pharmacy. The preparation method of the clindamycin phosphate injection comprises the following steps: sequentially and respectively dissolving the auxiliary materials edetate disodium and sodium hydroxide, then dissolving the raw material clindamycin phosphate to completely dissolve the raw material in a stable solution state, then complementing the water for injection, and carrying out multiple filter element filtration, filling, full plug pressing and capping to obtain the clindamycin phosphate injection. The clindamycin phosphate injection is obtained. The clindamycin phosphate injection obtained by the preparation method disclosed by the invention is good in quality.

The invention belongs to the technical field of dressings, and particularly relates to a gel dressing containing recombinant collagen as well as a preparation method and application of the gel dressing. The gel dressing containing the recombinant collagen is prepared from the following raw materials in percentage by weight: 0.1 to 1 percent of the recombinant collagen, 0.5 to 1 percent of sodium hyaluronate, 0.08 to 0.15 percent of radices stellariae dichotomae cyclopeptide, 0.5 to 1 percent of carbomer, 0.03 to 0.06 percent of cryptomeria fortunei bud extract, 15 to 20 percent of poloxamer, 0.1 to 0.5 percent of xanthan gum, 3 to 8 percent of glycerol, 0.04 to 0.08 percent of edetate disodium, 0.1 to 0.3 percent of triethanolamine, 0.08 to 0.12 percent of preservative and the balance of deionized water. The gel dressing has excellent biocompatibility, good hemostasis, cell growth promotion and tissue repair performance, and can be used for repairing vaginal mucous membrane chap and hemostasis of diffuse superficial bleeding, and improving the symptoms of elasticity reduction and the like caused by vaginal atrophy.

The invention provides a lactulose oral solution and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations, the oral solution comprises an active component lactulose, a solvent, a humectant, a stabilizer, a bacteriostatic agent and purified water; the stabilizing agent is prepared from hydroxypropyl chitosan and edetate disodium. The lactulose oral solution can overcome the defect of instability of lactulose through the cooperation of the stabilizer hydroxypropyl chitosan and edetate disodium, so that the lactulose oral solution has good stability.

The invention relates to an eye care solution capable of relieving eyeball aging, and belongs to the technical field of care solutions. The eye care solution capable of relieving eyeball aging is prepared from the following raw materials in percentage by mass: 1.5 to 2.5 percent of glycerol, 0.78 to 0.82 percent of sodium chloride, 0.01 to 0.02 percent of water-soluble lutein, 0.1 to 0.15 percent of taurine, 0.03 to 0.05 percent of hydrolyzed pearl, 0.2 to 0.28 percent of boric acid, 0.05 to 0.07 percent of borax, 0.02 to 0.04 percent of edetate disodium, 0.0035 to 0.0045 percent of benzalkonium chloride, 0.002 to 0.005 percent of borneol, 0.005 to 0.01 percent of menthol and the balance of purified water. The eye care solution disclosed by the invention aims at office workers who use eyes for a long time, middle-aged and elderly people who are susceptible to eyeball aging, asthenopia and dry eye surfaces, realizes mild moisturizing and relieving of the eye surfaces, supplements nutrients required by eye tissue metabolism, resists eyeball aging caused by light damage, and has the effects of relieving eye fatigue and relieving eye fatigue. Meanwhile, eyeball senescence related eye discomfort such as eye dryness, eye acerbity and blurred vision is relieved, bacteriostatic protection of the ocular surface microenvironment is considered, the physiological state of eye tissue can be improved after long-term use, and the eyeball senescence process is delayed.

The invention relates to the technical field of medicine, in particular to a metal ion complexing agent, a metronidazole gel preparation thereof and a preparation method of the metronidazole gel preparation. The first component is selected from at least one of disodium edetate, sodium calcium edetate and tetrasodium edetate; the second component is selected from at least one of sodium tartrate and sodium citrate; wherein the mass ratio of the first component to the second component is (8: 1)-(1: 6). The metronidazole gel preparation has the advantages that the preparation process is simple, the stability is better, and the safety and the effectiveness can be guaranteed.

The application relates to a shrinking and lubricating gel, which comprises the following raw materials in percentage by weight: xanthan gum 0.1-2%, trehalose 0.1-2%, carbomer 0.1-3%, glycerol 1-20%, gelatin alginate complex 1-10%, humectant 0.2-4%, disodium edetate 0.01-0.1%, polyethylene glycol 0.1-2%, pH regulator 0.1-3%, royal jelly extract 0-2%, schisandra extract 0-2%, and the balance is water. The application forms a protective biological gel layer on the vaginal wall through the lubricating gel, so as to prevent pathogenic microorganisms from planting, and is suitable for improving itching, erosion, burning, vaginal atrophy, sexual intercourse pain, senile vaginitis, abnormal leucorrhea, urinary urgency, dysuria and other menopausal reproductive urological syndromes.

The application discloses a benzalkonium chloride contraceptive gel for killing AIDS pathogens and a preparation method thereof, and belongs to the technical field of biological medicine manufacturing. The benzalkonium chloride contraceptive gel is prepared from water, hydroxypropyl methyl cellulose, polyquaternium-10, modified cyclodextrin, disodium edetate, benzalkonium chloride and glycerol in a specific proportion. In the preparation, the hydroxypropyl methyl cellulose and the polyquaternium-10 are first dispersed by heating, and then the water solution of the modified cyclodextrin, the disodium edetate and the benzalkonium chloride is sucked into the mixture after cooling, and the glycerol is added, and the finished product is obtained through cooling homogenization and vacuum degassing. Compared with the prior art, the amino acid grafted modified cyclodextrin enhances the inclusion and mucosal adhesion performance, the obtained gel has a fast inactivation rate for the AIDS pathogens, a long vaginal retention time, and has the high-efficiency antiviral and long-acting barrier effects, and has low irritation and is safe and reliable.

The application belongs to the technical field of pharmaceutical preparations, and particularly relates to a non-final sterilization production process for improving the stability of calcium folinate injection and application. The non-final sterilization production process for improving the stability of calcium folinate injection comprises the following steps: (1) dissolving calcium folinate in water for injection, adding sodium dihydrogen phosphate and disodium edetate, and adjusting the pH of the drug solution by using hydrochloric acid or sodium hydroxide solution; (2) filtering the drug solution through a 0.45-micron pre-filter filter core and a 0.22-micron terminal sterilization filter core in sequence; and (3) filling the drug solution into a container and sealing the container in an environment with a cleanliness of grade A. The process does not comprise a final sterilization step. The application reduces the risk of drug efficacy reduction and safety caused by drug degradation. Although the whole process does not comprise a final sterilization step, the sterility of the injection can be effectively guaranteed, and the risk of microbial contamination can be reduced. The production process is optimized, the production cost is reduced, and the application scenarios of the injection in clinical treatment are widened.

The invention provides a gel plaster containing Chinese ladiestresses root as well as a preparation method and application of the gel plaster, and relates to the technical field of gel plaster pharmaceutical preparations. An auxiliary material composition in the gel plaster is prepared from the following components in parts by weight: 0.3 to 0.8 part of eucalyptus globulus leaf oil, 0.5 to 3 parts of azone, 0.5 to 2 parts of polyethylene glycol hexadecyl ether, 3 to 8 parts of polyethylene glycol, 0.03 to 0.1 part of tert-butyl p-hydroxyanisole, 5 to 15 parts of carbomer, 0.01 to 0.05 part of edetate disodium, 0.05 to 0.3 part of gellan gum, 15 to 40 parts of glycerol, 0.2 to 0.8 part of sodium carboxymethyl cellulose, 0.05 to 0.5 part of a cross-linking agent and 125 to 250 parts of water. The components are mixed step by step, and the gel plaster is prepared by adopting a gradient heating and pressurizing homogenization method and a gradient cooling and depressurizing homogenization method, has excellent initial adhesion, adhesive force, permeability and stability, and has better effects of promoting blood circulation, relieving pain and diminishing swelling.

This invention relates to the field of pharmaceutical preparation technology, specifically to a sulfachlorpyridazine sodium-methotrexate suspension, its preparation method, and its application. The sulfachlorpyridazine sodium-methotrexate suspension of this invention comprises the following components per 100 ml: 20-50 g of sulfachlorpyridazine sodium, 4-10 g of methotrexate, 0.1-0.25 g of suspending agent, 0.05-0.125 g of wetting agent, 0.2-0.5 g of antioxidant, 0.1-0.25 g of disodium edetate, and purified water to a final volume of 100 ml. The suspension prepared by this invention can delay the in vivo clearance of sulfachlorpyridazine sodium, prolong the synergistic effect time, and improve its bioavailability; in the treatment of coccidiosis infection in chickens and sheep, it can significantly improve weight gain, reduce intestinal lesion values, rapidly clear oocysts, and maintain a long-lasting protective effect after drug withdrawal.

This invention belongs to the field of pharmaceutical formulation technology, specifically relating to a loratadine syrup and its preparation method. The syrup contains loratadine, a solubilizer, a thickener, a sweetener, a pH adjuster, a flavoring agent, an antibacterial agent, and a chelating agent. This invention optimizes the particle size requirements of the active pharmaceutical ingredient (API) and further optimizes the dissolution and mixing sequence of the various raw materials and excipients during syrup preparation, significantly reducing the dissolution time of the API. The loratadine syrup provided by this invention, with the addition of the chelating agent disodium edetate, exhibits significantly lower impurities after long-term storage compared to the original formulation, demonstrating excellent stability. This solves the existing problems of loratadine dissolution and insufficient stability.

The present application aims to provide a kind of norepinephrine bitartrate injection capable of effectively controlling norepinephrine sulfonate and product color and its preparation method, the present application is by norepinephrine bitartrate as active ingredient and edetate disodium, L-cysteine, sodium chloride, hydrochloric acid and water as excipients, and its preparation method, a kind of norepinephrine bitartrate injection specifically includes the following ingredients: 20g norepinephrine bitartrate, 80g sodium chloride, 2.5-3.0g edetate disodium, 4.0-5.0g L-cysteine per 10000ml, the scheme of the present application can effectively control norepinephrine sulfonate impurity and other oxidative impurities and product color.

The application belongs to the technical field of biological medicine, and particularly relates to an adrenaline injection and a preparation method thereof. The application provides an adrenaline injection, 1 mg of adrenaline, 9 mg of sodium chloride, 0.02%-0.5% of dihydrolipoic acid, 0.05%-0.5% of disodium edetate, and appropriate hydrochloric acid are contained in each 1 mL of the injection, and the rest is water for injection. The dihydrolipoic acid and the disodium edetate are innovatively added in the prescription as antioxidants, and the antioxidants synergistically play a stabilizing role. The prescription process of the application has good applicability and high stability, the injection can be subjected to terminal sterilization, and the safety and effectiveness of the product in the clinical use can be fully ensured.

This invention discloses a lyophilized formulation of fosfomycin sodium for injection and its preparation method. The lyophilized formulation comprises fosfomycin sodium, L-histidine, trehalose dihydrate, glycine, and disodium edetate, wherein L-histidine serves as a buffer component, trehalose dihydrate serves as an amorphous matrix protectant, glycine serves as a crystalline framework agent, and disodium edetate serves as a metal ion chelating agent. The preparation method includes solution preparation, pH adjustment and fine filtration, pre-freezing and annealing, primary drying, secondary drying, and nitrogen sealing. This invention, through the synergistic combination of quaternary excipients, specifically solves multiple technical problems in the fosfomycin sodium system, such as epoxy hydrolysis degradation, difficulties in lyophilization due to high sodium content, and extreme hygroscopicity. The resulting lyophilized formulation exhibits intact appearance, rapid reconstitution, and good stability.